Bausch Health Companies Expects 2024 Revenues Of $9.4B-$9.65B Versus Prior Guidance Of $9.3B-$9.55B And Consensus Of $9.397B, With Adjusted EBITDA Of $3.21B-$3.36B Vs. Prior Guidance Of $3.20B-$3.35B
Portfolio Pulse from Benzinga Newsdesk
Bausch Health Companies has updated its 2024 revenue guidance to $9.4B-$9.65B, up from the previous $9.3B-$9.55B and above the consensus of $9.397B. The company also raised its adjusted EBITDA guidance to $3.21B-$3.36B from the prior $3.20B-$3.35B.
August 01, 2024 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bausch Health Companies has increased its 2024 revenue and adjusted EBITDA guidance, surpassing both previous estimates and consensus expectations.
The upward revision in revenue and EBITDA guidance indicates stronger-than-expected performance, which is likely to positively impact BHC's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100